LIGAND PHARMACEUTICALS INC - 8-K Filing
Ligand Pharmaceuticals announced a proposed private offering of $550 million in convertible senior notes due 2031 and secured consent from its lenders to amend credit agreement terms, including lowering the minimum Consolidated EBITDA requirement for certain periods. The company also granted initial purchasers an option to purchase up to an additional $82.5 million in notes. (Items: 1.01 Entry into a Material Definitive Agreement, 8.01 Other Events, 9.01 Financial Statements and Exhibits)
Tickers: $LGND